Alzamend Neuro Inc 's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics

What is ROE for Alzamend Neuro Inc in the first quarter 2026?
Alzamend Neuro Inc recorded a cumulative net loss of $-9 million during 12 months ending in the first quarter 2026, resulting in a negative return on equity (ROE) of -244.56%.

Within the Major Pharmaceutical Preparations industry 366 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 3848 to 4327.

What is ROE?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Equity ROE▼

None ▼

Return on Equity ROE▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Equity	(Jul 31 2026) I. Quarter	(Apr 30 2026) IV. Quarter	(Jan 31 2026) III. Quarter	(Oct 31 2025) II. Quarter	(Jul 31 2025) I. Quarter
Y / Y Equity Change	8.59 %	-81.52 %	-	16.55 %	-
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in Millions	-9	-9	-8	-6	-7
Return On Equity (TTM)	-244.56 %	-243.36 %	-172.93 %	-233.42 %	-261.05 %
ALZN's Total Ranking	# 4327	# 3848	# 3934	# 4115	#
Equity (TTM) in Millions	6	1	4	4	5
Seq. Equity Change	691.41 %	-81.52 %	-9.28 %	-18.14 %	34.66 %
Seq. Net Income Change	-	-	-	-	-

Back to ALZN Management Effectiveness >> ALZN's 5 Years Annual ROE >> Compare ALZN ROE to its Competitors

Return On Equity Company Ranking
Within:	No.
Industry	# 367
Sector	# 763
Overall	# 4327

Return On Equity Statistics
High	Average	Low
-116.23 %	-356.76 %	-1505.24 %
(Apr 30 2022)		(Jan 31 2024)

ALZN Annual Return On Equity	(Apr 30 2026) 2026	(Apr 30 2025) 2025	(Apr 30 2024) 2024	(Apr 30 2023) 2023	(Apr 30 2022) 2022
Total Equity in Millions	1	4	-3	3	13
Y / Y Equity Change	-81.52 %	-	-	-77.19 %	1524.86 %
Net Income in Millions	9	-5	-10	-15	-12
Y / Y Net Income Change	-	-	-	-	-
Return On Equity	1200.2 %	-128.65 %	-	-488.53 %	-92.59 %

Back to ALZN Management Effectiveness >> ALZN's 5 Years Annual ROE >> Compare ALZN ROE to its Competitors

Annual Roe Comment

In 2026 ROE improved to 1200.2 % compared to the previous year, due to net income growth.

More Return On Equity Ratios
Major Pharmaceutical Preparations Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
ALZN's' Return on Equity at Yahoo Finance
ALZN's Roe Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for ALZN's Competitors
Subscribers only: Roe for Alzamend Neuro Inc 's Suppliers
Subscribers only: Return On Equity for ALZN's Customers

Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector

ROE

Date modified: 2026-09-18T15:21:03+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.